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Abstract 32 
 33 
Context 34 
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism and subfertility but 35 
the effects on mental health and child neurodevelopment are unclear.  36 
 37 
Objectives  38 
To determine if (i) there is an association between PCOS and psychiatric outcomes, and (ii) 39 
whether rates of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder 40 
(ADHD) are higher in children of mothers with PCOS. 41 
 42 
Design 43 
Data were extracted from the Clinical Practice Research Datalink. Patients with PCOS were 44 
matched to two control sets (1:1) by age, BMI and primary care practice. Control set 2 was 45 
additionally matched on prior mental health status. Primary outcomes were the incidence of 46 
depression, anxiety and bipolar disorder. Secondary outcomes were the prevalence of ADHD 47 
or ASD in the children.  48 
 49 
Results 50 
16,986 eligible patients were identified; 16,938 and 16,355 were matched to control sets 1 and 51 
2 respectively. Compared to control set 1, baseline prevalence was 23.1% versus 19.3% for 52 
depression, 11.5% versus 9.3% for anxiety and 3.2% versus 1.5% for bipolar disorder 53 
(p<0.001). The hazard ratio for time to each endpoint was 1.26 (95% CI 1.19-1.32), 1.20 (1.11-54 
1.29) and 1.21 (1.03-1.42) for set 1, and 1.38 (1.30-1.45), 1.39 (1.29-1.51) and 1.44 (1.21-1.71) 55 
for set 2. The odds ratios for ASD and ADHD in children were 1.54 (1.12-2.11) and 1.64 (1.16-56 
2.33) for set 1, and 1.76 (1.27-2.46) and 1.34 (0.96-1.89) for set 2. 57 
 58 
Conclusions 59 
PCOS is associated with psychiatric morbidity and increased risk of ADHD and ASD in their 60 
children. Screening for mental health disorders should be considered during assessment.  61 
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Précis 62 
Analysis of 17,000 patients with PCOS and controls found an increased incidence of 63 
psychiatric morbidity in women with PCOS, and increased risk of autism spectrum disorder 64 
and ADHD in their children. 65 
 66 
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Introduction 96 
Polycystic Ovary Syndrome is the commonest endocrine condition affecting young women, 97 
and is characterized by hyperandrogenism, menstrual disturbance and subfertility. In addition 98 
to its well-recognized reproductive sequelae (1), PCOS is now established as a metabolic 99 
disorder underpinned by insulin resistance and leading to an increased risk of type 2 diabetes 100 
(2).  101 
 102 
The cutaneous manifestations of hyperandrogenism, including hirsutism, acne and scalp hair 103 
loss, are emotionally distressing (3, 4), and could contribute to an increased prevalence of 104 
depression and anxiety in this population (5-8). Comorbid mental health disorders have also 105 
been shown to contribute to impaired quality of life in PCOS (9). However, it is difficult to 106 
establish how many of these outcomes are attributable to PCOS per se, and how many to 107 
obesity, which is common in this patient group and itself associated with adverse mental health 108 
outcomes, including depression (10) and anxiety (11). This risk of depression may be 109 
particularly increased in patients with metabolically unhealthy obesity, which is characterized 110 
by insulin resistance and abdominal adiposity (12), compared to metabolically healthy weight-111 
matched controls (13, 14). Furthermore, in community-based studies, the association between 112 
obesity and depression appears stronger for women compared to men (15). This association 113 
may be bi-directional: in longitudinal studies obesity increases the risk of a subsequent 114 
diagnosis of depressive disorder, whilst depression at baseline in turn increases the odds for 115 
developing obesity (16). This latter risk appears to be particularly high for adolescent females 116 
(16).    117 
 118 
Whilst previous studies have focused on the risk of depressive disorder and anxiety in patients 119 
with PCOS, hyperandrogenism may also influence the risk of other mental health disorders 120 
including schizophrenia (17). However, a recent population-based cohort study failed to 121 
demonstrate an increased risk of developing schizophrenia (or bipolar disorder) in women with 122 
PCOS, although an increased risk of depressive disorder, anxiety disorder and sleep disorder 123 
was confirmed (18).  Other studies have shown that the risk of eating disorder, notably binge-124 
eating disorder, may be increased in women with PCOS (19, 20). Attention deficit 125 
hyperactivity disorder (ADHD) has also been shown to associate with hyperandrogenism (21) 126 
and obesity in adults (22), albeit that the latter effect size is moderate,  127 
 128 
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More recently, these studies have been extended to examine the influence of intra-uterine 129 
androgen exposure on neurodevelopmental outcomes in the children of mothers with PCOS. 130 
Brain development is influenced significantly by exposure to androgens during early gestation. 131 
Female rhesus monkeys exposed in utero to androgens show increased male-type behavior (23) 132 
whilst both attention-deficit hyperactivity disorder (ADHD) and autism spectrum disorder is 133 
more likely to be diagnosed in males than females (24, 25). These observations suggest that 134 
ADHD and ASD may be influenced by prenatal androgen exposure. One small case-control 135 
study has suggested that women with PCOS may have higher scores on ADHD symptoms on 136 
self-report scales (26) whilst we have recently shown that white matter microstructure is altered 137 
in young women with PCOS (27). Most recently, Kosidou et al, in a matched case-control 138 
study, found that maternal PCOS increased the odds of ASD in the children by 59%, which 139 
was further exacerbated by concomitant obesity (28). These studies require confirmation but 140 
suggest that PCOS may represent a novel risk-state for later life neurodevelopmental disorders.  141 
 142 
Although these observations suggest that PCOS may be associated with several adverse mental 143 
health outcomes, many studies are limited by a failure to match for obesity (a potential major 144 
confounder), small sample sizes, cross-sectional study designs and assessment of psychiatric 145 
morbidity using rating scales, rather than formal diagnosis by a psychiatrist or other clinician. 146 
In light of these uncertainties, we sought to establish the relative risks of major mental health 147 
outcomes (depressive disorder, anxiety, bipolar disorder, schizophrenia, eating disorder, 148 
ADHD and ASD) for patients with PCOS, and neurodevelopmental disorders (ASD and 149 
ADHD) in children born to mothers with PCOS. 150 
  151 
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Materials and Methods 152 
The study employed a retrospective cohort design using data from the Clinical Practice 153 
Research Datalink (CPRD), a longitudinal, anonymized research database collected from 674 154 
primary care practices in the United Kingdom. The CPRD contains records for over 11 million 155 
patients and is representative of the UK population in terms of age and sex (29). Approximately 156 
60% of practices participate in a linkage scheme, by which their patient records are linked to 157 
other data sources, including the Hospital Episode Statistics (HES) dataset, which provides 158 
data on all inpatient and outpatient contacts occurring within National Health Service hospitals 159 
in England, and the Office for National Statistics (ONS) mortality dataset. Diagnostic 160 
information in the CPRD primary-care dataset is recorded using the Read code classification, 161 
a UK primary-care practice standard. HES inpatient data are recorded using the ICD-10 162 
classification. 163 
 164 
Patient selection and matching of controls  165 
The study was conducted using data from CPRD’s primary-care (GOLD) and linked HES data 166 
sets. The study population were those patients flagged by CPRD as being of an acceptable 167 
research quality. Patients with a diagnosis of PCOS recorded in the primary care dataset using 168 
the Read code classification (C164.00, C164.12, C165.00) from 2000 to 2014 were selected. 169 
The earliest diagnosis date was selected as the index date. A minimum “wash-in” period of 6 170 
months from the patient’s practice registration date to index date was used to maximize the 171 
likelihood that the case represented an incident case.  172 
 173 
Patients identified with PCOS were matched at a ratio of 1:1 to two sets of non-PCOS controls. 174 
This was to allow for the baseline prevalence of the selected outcomes for patients with PCOS 175 
to be calculated relative to non-PCOS controls using matching criteria 1. Matching criteria 2 176 
allowed for patients to be matched on mental health history to identify the incidence of 177 
outcomes following PCOS diagnosis. For control set 1, cases with PCOS were matched to 178 
controls with no history of PCOS; the controls took the index date of the case. All controls 179 
were required to have at least a 6-month wash-in period from registration at the practice to the 180 
case index date. Controls were matched by age (± 2 years), BMI category (<25 kg/m2, 25-30 181 
kg/m2, >30 kg/m2) and primary care practice. The same matching criteria were applied to 182 
control set 2, who were additionally matched for a history of prior mental health disorder 183 
(depression, anxiety, bipolar disorder, schizophrenia, eating disorder, autism, ADHD). 184 
Controls could appear in both sets. Mental health disorders were defined by the Read code 185 
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classification or 10th revision of the International Statistical Classification of Diseases and 186 
Related Health Problems (ICD-10) classification (Supplementary appendix 1).  187 
 188 
Endpoints 189 
Primary outcomes were the incidence of depressive disorder, anxiety, bipolar disorder, 190 
schizophrenia, eating disorder, ADHD and autism spectrum disorder in cases and controls. 191 
Secondary outcomes were the prevalence of ADHD or autism spectrum disorder in the children 192 
of mothers with PCOS. Children were identified via the mother-baby link generated within 193 
CPRD which links mothers with their children. To maximize patient numbers, births both 194 
before and after index date were included in this study. 195 
 196 
Data analysis  197 
Baseline characteristics between cases and controls were compared using univariate statistics 198 
(t-test for continuous variables and χ2 for categorical variables). Crude rates of progression to 199 
each outcome were presented and time to each endpoint was analyzed using Cox proportional 200 
hazard models (CPHM). The Cox models included the following covariates (all were available 201 
and tested for inclusion in each model): age, BMI, smoking status, baseline morbidity 202 
represented by the Charlson index (30), total number of contacts with the general practitioner 203 
in the year before index date that is regarded as a proxy for general morbidity, and deprivation 204 
based on quintiles of Index of Multiple Deprivation (IMD). The IMD is an area-based measure 205 
of social and material deprivation based upon various criteria including income and education. 206 
Covariates were entered into each model if they were significant in that model. Threshold 207 
statistical significance was p ≤0.05, and 95% confidence intervals (CI) were given for hazard 208 
ratios (HR).   209 
Multivariate logistic regression was used to examine the association of PCOS status with risk 210 
of autism spectrum disorder and ADHD in the children.  211 
 212 
A sensitivity analysis exploring the association of bipolar disorder with PCOS was undertaken, 213 
excluding cases who had been treated with valproate therapy prior to index date. 214 
 215 
Studies using CPRD are covered by ethics approval granted by Trent Multicentre Research 216 
Ethics Committee (Reference 05/MRE04/87). CPRD Independent Scientific Advisory 217 
Committee approval was granted for this study (ISAC 16-249). 218 
219 
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Results 220 
 221 
89,732 patients with PCOS were initially identified. After application of the 222 
inclusion/exclusion criteria, 16,986 patients remained eligible for matching with control 223 
subjects (figure 1). 16,938 (99.7%) and 16,355 (96.3%) patients could be matched with controls 224 
for control sets 1 and 2 respectively. 225 
 226 
Baseline characteristics 227 
The baseline characteristics of patients with PCOS and controls are shown in tables 1 and 2 228 
respectively for control sets 1 and 2. For control set 1, median follow-up was 3.87 years 229 
(interquartile range (IQR) 1.80-7.25) for cases and 2.81 years (IQR 1.20-5.80) for controls. For 230 
control set 2, median follow-up was 3.88 years (IQR 1.81-7.26) for cases and 3.07 years (IQR 231 
1.32-6.70) for controls. In both control sets, there were significant differences between cases 232 
and controls. Patients with PCOS had increased primary care contacts in the year prior to index 233 
date (median 6.0 contacts versus 4.0 for both control sets), and an increased proportion of 234 
patients classified with extreme obesity (6.7% vs 3.9% in control set 1 and 6.3% vs 3.8% in 235 
control set 2). In addition, there were significant differences in smoking status, alcohol history 236 
and systolic and diastolic blood pressure. 237 
 238 
Prevalence of mental health disorders 239 
In control set 1, 3,912 (23.1%) patients with PCOS had previously been diagnosed with 240 
depression compared to 3,272 (19.32%) of controls (p<0.00001) (Supplementary appendix 241 
2). A prior diagnosis of anxiety was also higher in patients with PCOS (n=1,956, 11.55%) 242 
compared to controls (n=1,579, 9.32%) (p<0.00001). There was also a significant increase in 243 
the recorded diagnosis of bipolar disorder (PCOS 535 (3.16%) vs 384 (1.45%) controls, 244 
p<0.00001). Prior diagnosis of eating disorder for patients with PCOS was higher (n=262, 245 
1.55%) than controls (n=175, 1.03%) (p=0.00003). In the sensitivity analysis excluding pairs 246 
of cases and controls where either had been treated with valproate therapy prior to index date, 247 
the rate of bipolar disorder remained significantly greater for patients with PCOS (526 248 
(3.14%) versus 375 (1.45%); p <0.00001). 249 
 250 
There were no significant differences in the prevalence of schizophrenia, autism spectrum 251 
disorder or ADHD between cases and controls (Supplementary appendix 2).  252 
 253 
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Incidence of mental health disorders  254 
For control set 1 the rate of depression following index date was 42.62 per 1,000 patient years 255 
(pky) for patients with PCOS compared with 34.46 pky for controls. The respective figures for 256 
anxiety, bipolar disorder and eating disorder were 21.99 pky versus 17.61 pky, 4.83 pky versus 257 
3.64 pky, and 7.57 pky versus 4.36 pky (Table 3). For control set 2 the rates were 41.66 pky 258 
versus 26.66 pky for depression, 21.33 pky versus 12.64 pky for anxiety, 4.42 pky versus 2.48 259 
pky for bipolar disorder, and 7.40 pky versus 3.95 pky for eating diosorder. 260 
 261 
 262 
Hazard ratios for mental health disorders 263 
Time to event for depression and anxiety for both control sets are shown in the Kaplan-Meier 264 
curves in figure 2. After adjusting for demographic and morbidity indicators in the Cox 265 
proportional hazards model, the hazard ratios for patients with PCOS compared to controls in 266 
control set 1 were 1.26 (95% CI 1.19-1.32) for depression, 1.20 (95% CI 1.11-1.29) for anxiety,  267 
1.21 (95% CI 1.03 – 1.42) for bipolar disorder and 1.37 (95% CI 1.05-1.81) for eating disorder.  268 
For control set 2 the hazard ratios were 1.38 (95% CI 1.30-1.45) for depression, 1.39 (95% CI 269 
1.29-1.51) for anxiety and 1.54 (95% CI 1.16-2.05) for eating disorder. Due to model violations 270 
it was not possible to calculate the hazard ratio for bipolar disorder (Table 3). 271 
 272 
In the sensitivity analysis excluding cases who had been treated with valproate therapy prior to 273 
index date the HR for cases to controls for bipolar disorder was 1.21 (95% CI 1.03-1.42) for 274 
control set 1 and 1.45 (95% CI 1.21-1.73) for control set 2. 275 
 276 
ADHD and Autism Spectrum Disorder in children of patients with PCOS 277 
In control set 1 there were 8,962 children born to patients with PCOS compared to 8,885 born 278 
to the controls. The respective rate of ADHD was 4.81 pky versus 3.32 pky with an odds ratio 279 
of 1.64 (95% CI 1.16-2.33). The rate of ASD was 5.82 pky versus 3.92 pky; odds ratio 1.54 280 
(95% CI 1.12-2.11).  In control set 2, there were 8,695 births to women with PCOS and 8,973 281 
to controls. The rate of ADHD was 6.00 pky versus 3.54 pky; odds ratio 1.75 (1.27 – 2.46) and 282 
the rate of ASD was 4.44 pky versus 3.90 pky; odds ratio 1.34 (95% CI 0.96-1.89) (Table 4). 283 
 284 
  285 
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Discussion 286 
In this large retrospective database analysis we have reported a significantly increased 287 
prevalence of depression, anxiety, bipolar disorder and eating disorder at the time of diagnosis 288 
with PCOS compared to matched controls. There was no difference in rates of clinically 289 
recorded ASD, ADHD or schizophrenia, though the background rate of these conditions 290 
resulted in the study being under-powered for these conditions. The incidence of these 291 
conditions following index date was also increased for patients with PCOS. In addition, we 292 
have reported increased rates of ASD and ADHD in the children of women with PCOS 293 
compared with controls. 294 
 295 
Our findings of an increased prevalence of depression and anxiety in women with PCOS are 296 
consistent with a number of cross-sectional studies using screening tools such as the Beck 297 
Depression/Anxiety Inventory or the Hospital Anxiety and Depression Scale (HADS). This 298 
risk is maintained even when only moderate-to-severe symptoms are considered and when the 299 
diagnosis is made by a psychiatrist (31, 32). We also observed an increased incidence of 300 
depression and anxiety when we matched patients and controls for a prior history of mental 301 
health disorder. Similarly increased risks of developing depression and anxiety with time have 302 
been found in Taiwanese (17) and Australian (33) patients with PCOS.  303 
 304 
A number of potential mechanisms may be in operation. Obesity, which is itself associated 305 
with depression and anxiety (9, 10), is a common co-morbidity in women with PCOS and could 306 
explain some of this risk. However, in a systematic review and meta-analysis of cross-sectional 307 
studies (32), the increased odds of depressive and anxiety symptoms persisted even when 308 
subjects with PCOS were matched on BMI with controls, indicating that factors other than 309 
obesity must be contributing. Hyperandrogenism is a hallmark of PCOS and may lead to the 310 
emotionally distressing symptoms of hirsutism and acne. High patient-rated Ferriman-Gallwey 311 
scores, as a measure of hirsutism, have been associated with higher HADS depression and 312 
anxiety scores in women presenting to dermatology clinics for hair removal (34). Ferriman-313 
Gallwey scores were also increased in PCOS subjects with anxiety and depression symptoms, 314 
and free testosterone levels were higher in women with PCOS and anxiety compared to those 315 
with no anxiety (32). However, the relationship between androgen levels and affective 316 
symptoms may not be so clear-cut since others have shown an association of lower testosterone 317 
and androgen metabolite concentrations with worse self-reported depression symptoms in 318 
women with PCOS (35). Increased changes in testosterone concentrations across the 319 
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perimenopause have also been associated with depression (36, 37). Fertility may be another 320 
major concern for women with PCOS, although depression and anxiety scores remain higher 321 
than controls in studies where this has been accounted for (32, 38). Of interest, insulin 322 
resistance has also been proposed as a potential mechanism by which depression and anxiety 323 
might be increased in PCOS. Insulin resistance, a characteristic of both lean and overweight 324 
patients with PCOS, shows a bidirectional relationship with depression in the general 325 
population (39) whilst in a recent study of PCOS subjects, insulin resistance was associated 326 
with depression risk independently of age, BMI, ethnicity and exercise (40).      327 
 328 
In contrast to depression and anxiety, only a few studies have examined the risk of other 329 
psychiatric disorders in women with PCOS. However, two population-based studies have 330 
shown that the risk of mental health disorders in PCOS may be broader than previously 331 
recognized, with increased odds of bipolar disorder, schizophrenia, personality disorders, 332 
autism spectrum disorder, bulimia and tics, in addition to depression and anxiety (17, 41).  333 
Whilst we were underpowered to show an effect of PCOS on autism spectrum disorder, ADHD 334 
and schizophrenia, we did confirm an increased prevalence and incidence of bipolar disorder 335 
compared to matched controls. Valproate therapy could, at least in part, explain this association 336 
since symptoms compatible with PCOS have been reported in women treated for bipolar 337 
disorder with valproate (42). However, other studies have shown that symptoms pre-date 338 
treatment (43). Furthermore, in keeping with another registry study (41) we found that this 339 
association, although slightly attenuated, persisted when excluding subjects treated with 340 
valproate before diagnosis. The prevalence and incidence of eating disorder was also higher in 341 
patients with PCOS. This is in keeping with other studies (19, 20), which have shown an 342 
association of binge-eating with menstrual dysfunction (44), and a higher rate of eating 343 
disorders in women with PCOS especially in the presence of concurrent anxiety (20).  344 
 345 
Since the intra-uterine environment is known to be important in regulating child 346 
neurodevelopment, we were also keen to examine the effect of maternal PCOS status (and 347 
potential hyperandrogenism) on the risk of neurodevelopmental disorders in their children. Our 348 
linkage analysis found an increased risk of a recorded diagnosis of ASD and ADHD in children 349 
born to mothers with PCOS. This is in agreement with the observations of Kosidou et al (25, 350 
45), who reported respectively increased risks of 59% and 42%, of a similar magnitude to our 351 
data. They have recently extended their observations in relation to ASD to report an increased 352 
risk in mothers with a diagnosis of hirsutism (46). These data support the view that increased 353 
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exposure to androgens in utero might adversely influence brain development. Indeed, intra-354 
amniotic Δ4 sex-steroid levels, including testosterone and androstenedione, were found to be 355 
higher in mothers of children who subsequently developed ASD than those who did not (47). 356 
PCOS might expose the developing fetus to excess androgens since women with PCOS show 357 
increased circulating androgen levels during gestation and have greater placental androgenic 358 
capacity (48-50). Prenatal androgen exposure might increase ASD and ADHD risk through 359 
effects on dendritic morphology, neuronal density, abnormal synapse function and morphology 360 
(51, 52). In this regard, our recent findings of altered white matter microstructure in women 361 
with PCOS, notably in androgen-sensitive areas such as the corpus callosum (27), are 362 
intriguing and merit further investigation. Maternal androgen excess might also predispose to 363 
anxiety in the children of mothers with PCOS: in a rodent model, prenatal androgen exposure 364 
resulted in increased anxiety-like behavior in offspring, mediated via androgen receptor 365 
activation in the amygdala and accompanied by changes in serotonergic and GABAergic genes 366 
in the amygdala and hippocampus (53).  367 
 368 
Whilst environmental influences such as androgen exposure may go some way to explaining 369 
the effects of PCOS on mental health risk, other explanations for these findings also merit 370 
consideration. In a nationwide Swedish registry study, Cesta et al found a higher risk for a 371 
range of psychiatric disorders not only in PCOS subjects but also in their siblings (41). 372 
Endocrine disturbances could account for these findings since nearly 50% of sisters of women 373 
with PCOS are hyperandrogenic (54) whilst their brothers also have alterations in gonadotropin 374 
and steroidogenic hormone secretion (55). Alternatively, shared familial factors between 375 
PCOS and psychiatric disorders may exist, including a common genetic predisposition as well 376 
as shared psychosocial factors in childhood.  377 
 378 
Our study has a number of strengths, especially the large, population-based sample and 379 
adjustment for a number of potential confounders. However, our study also has limitations. As 380 
with all database studies, there is the possibility of confounding and bias that should be 381 
considered when interpreting these results. Patients with PCOS had significantly increased 382 
primary care contacts in the 12 months prior to baseline (6 versus 4 in both control sets). This 383 
may be due to consultations relating to symptoms and investigations relevant to the PCOS 384 
diagnosis, but they may also relate to the prevalence of other conditions which may be 385 
associated with other health-related morbidities.  386 
 387 
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Observation bias may also be a factor in these results, as patients with increased contacts with 388 
health professionals necessitated by the presence of a condition such as PCOS have increased 389 
chance of other conditions such as depression and anxiety being diagnosed and recorded within 390 
the dataset. We deliberately used a broad range of codes to determine depression and anxiety 391 
as there is evidence that over the study time period there has been a shift in primary care such 392 
that the recording of clinical diagnoses of depression has reduced whilst the recording of 393 
depressive symptoms has increased. Overall, however, the combined rate for the incidence of 394 
diagnoses and symptoms has remained relatively stable (56). It is possible, however, that some 395 
symptom terms such as ‘Feeling depressed’ may be less indicative of clinically relevant 396 
depression than diagnosis terms such as ‘Chronic depression’. Whilst there may be some 397 
ambiguity surrounding depression and anxiety this is less likely for bipolar disorder which was 398 
increased in the population with PCOS compared with controls. 399 
 400 
There was significant missing data in this study. Body mass index was not available for over 401 
50% of cases although obesity is known to be associated with depression and anxiety (9, 10) 402 
and also with PCOS. To compensate for this we modelled BMI as a categorical variable with 403 
missing included as a category, but it should be considered that different levels of BMI within 404 
the ‘missing’ category could partially explain some of the observed results in this study. 405 
 406 
In conclusion, our study confirms that women with PCOS are at increased risk of being 407 
diagnosed with depression, anxiety, bipolar disorder and eating disorder, and that their children 408 
are at increased risk of a diagnosis of autism spectrum disorder and ADHD. Our data support 409 
international guidelines which recommend screening for mental health disorders as part of the 410 
comprehensive clinical care for women with this condition (57, 58). Further research is critical 411 
in understanding the mechanisms by which these risks arise in order to optimise interventions 412 
to reduce psychiatric morbidity.  413 
 414 
 415 
 416 
 417 
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Table 1 Baseline characteristics for women with PCOS and matched controls – control set 1 666 
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  667 
Baseline Characteristics Case Control p-value 
Total, n (%) 16,938 100.00 16,938 100.00  
Age (years), mean, SD 26.90 7.20 27.01 7.36 0.1983 
Follow-up (years), median, LQ-UQ 3.87 1.80 - 7.25 2.81 1.20 - 5.80 <0.0001 
Observation period pre-index (years), 
median, LQ-UQ 
4.33 1.90 - 9.10 3.32 1.48 - 7.59 <0.0001 
Primary care contact in prior year, 
median, LQ-UQ 
6 3 - 9 4 1 - 7 <0.0001 
BMI (kg/m2), mean, SD 29.86 7.86 28.99 7.01 <0.0001 
BMI (kg/m2)     <0.0001 
    Underweight, (<20), n(%) 653 3.86 663 3.91  
    Normal, (20-24), n(%) 1,652 9.75 1,683 9.94  
    Overweight, (>24-29), n(%) 1,885 11.13 1,938 11.44  
    Obesity, (>29-39), n(%) 2,955 17.45 3,335 19.69  
    Extreme Obesity, (>39), n(%) 1,133 6.69 659 3.89  
    Missing, n(%) 8,660 51.13 8,660 51.13  
Smoking     <0.0001 
    Never, n(%) 10,540 62.23 10,333 61  
    Prior,  n(%) 2,934 17.32 2,559 15.11  
    Current, n(%) 4,394 25.94 4,918 29.04  
    Missing, n(%) 174 1.03 727 4.29  
Alcohol     <0.0001 
    Never, n(%) 3,525 20.81 3,181 18.78  
    Prior, n(%) 240 1.42 229 1.35  
    Current, n(%) 9,713 57.34 9,812 57.93  
    Missing, n(%) 3,460 20.43 3,716 21.94  
Diastolic BP     <0.0001 
Diastolic BP (mmHg), mean, SD 74.97 9.82 73.52 9.55 <0.0001 
     <80, n(%) 6,128 36.18 6,878 40.61  
     80-89,n(%) 2,913 17.2 2,783 16.43  
    >89, n(%) 697 4.12 468 2.76  
    Missing, n(%) 7,200 42.51 6,809 40.2  
Systolic BP     <0.0001 
Systolic BP (mmHg), mean, SD 118.78 13.78 117.89 13.26 <0.0001 
     <120, n(%) 4,782 28.23 5,201 30.71  
    120-139, (%) 4,170 24.62 4,286 25.3  
    >139, n(%) 786 4.64 642 3.79  
    Missing, n(%) 7,200 42.51 6,809 40.2  
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Table 2 Baseline characteristics for women with PCOS and matched controls – control set 2 668 
 669 
  670 
Baseline Characteristics Case Control p-value 
Total, n(%) 16,355 100.00 16,355 100.00  
Age (years), mean, SD 26.93 7.21 27 7.37 0.3997 
Follow-up (years), median, LQ-UQ 3.88 1.81 - 7.26 3.07 1.32 - 6.70 <0.0001 
Observation period pre-index (years), 
median, LQ-UQ 
4.30 1.89 - 9.05 3.67 1.63 - 8.13 <0.0001 
Primary care contact in prior year, 
median, LQ-UQ 
6 3 - 9  4 1 - 7 <0.0001 
BMI (kg/m2), mean, SD 29.68 7.83 28.84 7.07 <0.0001 
BMI (kg/m2)      <0.0001 
    Underweight, (<20), n(%) 632 3.86 664 4.06  
    Normal, (20-24), n(%) 1,600 9.78 1,594 9.75  
    Overweight, (>24-29), n(%) 1,789 10.94 1,842 11.26  
    Obesity, (>29-39), n(%) 2,721 16.64 3,052 18.66  
    Extreme Obesity, (>39), n(%) 1,027 6.28 617 3.77  
    Missing, n(%) 8,586 52.5 8,586 52.5  
Smoking     <0.0001 
    Never, n(%) 10,051 61.46 10,231 62.56  
    Prior,  n(%) 2,459 15.04 2,970 18.16  
    Current, n(%) 4,185 25.59 4,652 28.44  
    Missing, n(%) 170 1.04 749 4.58  
Alcohol     <0.0001 
    Never, n(%) 3,403 20.81 3,052 18.66  
    Prior, n(%) 218 1.33 237 1.45  
    Current, n(%) 9,378 57.34 9,342 57.12  
    Missing, n(%) 3,356 20.52 3,724 22.77  
Diastolic BP     <0.0001 
Diastolic BP (mmHg), mean, SD 74.9 9.82 73.27 9.58 <0.0001 
     <80, n(%) 5,887 36 6,765 41.36  
     80-89,n(%) 2,773 16.96 2,496 15.26  
    >89, n(%) 652 3.99 464 2.84  
    Missing, n(%) 7,043 43.06 6,630 40.54  
Systolic BP     <0.0001 
Systolic BP (mmHg), mean, SD 118.71 13.78 117.85 13.06 <0.0001 
     <120, n(%) 4,576 27.98 4,999 30.57  
    120-139, (%) 3,991 24.4 4,110 25.13  
    >139, n(%) 745 4.56 616 3.77  
    Missing, n(%) 7,043 43.06 6,630 40.54  
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Table 3 Number, crude rates and associated hazard ratios for depression, anxiety and bipolar disorder in women with PCOS and matched controls 
pky: per 1,000 person years   
 Cases Controls Hazard Ratio (CI) p-value 
 Number (Rate pky) Number (Rate pky)   
Control set 1 16,938  16,938    
Depression 3,545 42.62 2,327 34.46 1.26 (1.19 – 1.32) <0.00001 
Anxiety 1,829 21.99 1,189 17.61 1.20 (1.11 – 1.29) <0.00001 
Bipolar Disorder 402 4.83 246 3.64 1.21 (1.03 – 1.42) 0.02126 
Autism 14 0.83 16 0.94   
ADHD 13 0.77 11 0.65   
Schizophrenia 22 1.30 9 0.53   
Eating Disorder 125 7.57 72 4.36 1.37 (1.05 – 1.81) 0.02283 
Control set 2 16,355  16,355    
Depression 3,353 41.66 2,146 26.66 1.38 (1.30 – 1.45) <0.00001 
Anxiety 1,717 21.33 1,017 12.64 1.39 (1.29 – 1.51) <0.00001 
Bipolar Disorder 356 4.42 200 2.48   
Autism 9 0.55 3 0.18   
ADHD 8 0.49 6 0.37   
Schizophrenia 10 0.61 6 0.37   
Eating Disorder 118 7.40 63 3.95 1.54 (1.16 - 2.05) 0.00256 
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 Table 4 Number, rate and odds ratio of ADHD and autism in the children of mothers with PCOS and matched controls 
pky: per 1,000 person years 
Mental Health Disorder Cases Controls Odds Ratio (CI) p-value 
  Number (Rate pky) Number (Rate pky)     
Control set 1 8,962  8,885    
ADHD 81 4.81 56 3.32 1.64 (1.16 – 2.33) 0.00526 
Autism 98 5.82 67 3.98 1.54 (1.12 – 2.11) 0.00068 
Control set 2 8,695  8,973    
ADHD 74 4.44 65 3.90 1.34 (0.96 – 1.89) 0.08708 
Autism 95 6.00 59 3.54 1.75 (1.27 – 2.46) 0.00080 
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Figure 1 Attrition chart for identification of pool of patients with PCOS  
 
Figure 2 | Kaplan-Meier curves showing time to depression and anxiety for patients with PCOS 
compared to matched controls. 
 
  
  
  
 
